Duchenne Muscular Dystrophy (DMD) Treatment Market Size, Share, Opportunities, And Trends By Tests (Blood Test, Molecular, Genetic Testing, Electromyography, Muscle Biopsy), By Treatment (Physical Therapy, Orthopedic Devices, Steroids, Others), And Geography - Forecasts From 2019 To 2024

Published: Mar 2020 | Report Code:  KSI061612301 | Pages:  98

The Duchenne Muscular Dystrophy (DMD) treatment market is estimated to be valued at US$981.367 million in 2018 and is expected grow steadily during the forecast period. Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the mutation of the DMD gene, which is responsible for making a protein called dystrophin causing progressive muscle degeneration. At present, there is no cure for the disease, certain research strategies are being worked upon, however, the treatment is provided for the mitigation of disease symptoms. The growing incidence of rare diseases, rising R&D investments, growing adoption of genetic testing worldwide are some of the major drivers driving the growth of the Duchenne muscular dystrophy (DMD) treatment market during the forecast period. Furthermore, growing awareness regarding self-care and self-management resulting in early disease detection will help in the disease management in an efficient manner leading to sustainable market growth in the near future and beyond. The prevalence of Duchenne and Becker muscular dystrophy (DBMD) among Non-Hispanic blacks were lower than the prevalence among Hispanics and Non-Hispanic whites (Centers for Disease Control and Prevention, CDC). Thus, owing to high disease prevalence, North America and Europe are expected to hold a significant market share globally.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Duchenne muscular dystrophy (DMD) treatment value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics for providing a faster and efficient understanding of the Duchenne muscular dystrophy (DMD) treatment market.
Major industry players profiled as part of the report are Pfizer Inc., Sarepta Therapeutics, Inc., ReveraGen BioPharma, Inc., PTC Therapeutics, and NIPPON SHINYAKU CO., LTD. among others.
The duchenne muscular dystrophy (DMD) treatment market has been analyzed through following segments:
By Tests
Blood Test
Molecular Genetic Testing
Muscle Biopsy
By Treatment
Physical Therapy
Orthopedic Devices
By Geography
North America
South America
United Kingdom
Middle East and Africa
Saudi Arabia
Asia Pacific
South Korea